Gansu Provincial Hospital

Running trials

• Recruiting

  Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre

  NCT07687186· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Not yet recruiting

  The Correlation of Postoperative Polyp Recurrence and Colorectal Cancer

  NCT07708415· Gansu Provincial Hospital· Source

• Recruiting

  A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

  NCT07593027· Phase 1/2· ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.· Source

• Recruiting

  Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

  NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Recruiting

  Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

  NCT07464587· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

  NCT07447986· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

  NCT07230119· Phase 3· Beijing QL Biopharmaceutical Co.,Ltd· Source

• Recruiting

  Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

  NCT07263308· Phase 3· Capital Medical University· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

  NCT07187960· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Active, not recruiting

  A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

  NCT07245407· AstraZeneca· Source

• Recruiting

  A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

  NCT07202884· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

  NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

  NCT06949033· Phase 3· Zuoyi Jiao· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

  NCT06925243· Phase 3· Zuoyi Jiao· Source

• Recruiting

  TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

  NCT06829784· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Recruiting

  A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors（G-MAP 101）

  NCT06796699· Phase 1· Suzhou Genhouse Bio Co., Ltd.· Source

• Recruiting

  A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

  NCT06532006· Phase 3· Shanghai Henlius Biotech· Source

• Active, not recruiting

  A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

  NCT06561607· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Active, not recruiting

  SIM0718 Treatment of Asthma Clinical Study

  NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· LeonaBio· Source

• Active, not recruiting

  Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

  NCT06577792· Sun Yat-sen University· Source

• Recruiting

  Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

  NCT05866029· Peking Union Medical College Hospital· Source

• Recruiting

  Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

  NCT05862337· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Active, not recruiting

  A Study of Telitacicept for IgA Nephropathy (TELIGAN)

  NCT05799287· Phase 3· RemeGen Co., Ltd.· Source

• Not yet recruiting

  Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

  NCT04995159· Lepu Medical Technology (Beijing) Co., Ltd.· Source

• Active, not recruiting

  Newly Diagnosed Glioblastoma

  NCT04959500· Phase 2· Sun Yat-sen University· Source

• Active, not recruiting

  A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

  NCT04854668· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Active, not recruiting

  Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)

  NCT06524427· Sun Yat-sen University· Source

• Active, not recruiting

  A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

  NCT04344158· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer4 recruiting
• COPD2 recruiting
• Coronary artery disease2 recruiting
• Obesity2 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• IgA nephropathy1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Metastatic breast cancer1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoporosis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

  NCT07807007· Phase 2· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source

• Completed

  A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

  NCT06738979· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

  NCT06029127· Phase 2· BeiGene· Source

• Completed

  A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

  NCT06103825· Phase 3· Ignis Therapeutics (Suzhou) Limited· Source

• Completed

  Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale

  NCT05546320· Phase 2· Chinese Academy of Medical Sciences, Fuwai Hospital· Source

• Terminated

  A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

  NCT05292196· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

  NCT04574284· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Gastric and oesophageal cancer42 works · 4 trials
• Aplastic anaemia3 works · 0 trials